Statins against drug-induced nephrotoxicity

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 4, 2013, Pages 588-608

  Dashti Khavidaki, Simin ^a   Moghaddas, Azadeh ^a   Heydari, Behrooz ^a   Khalili, Hossein ^a   Lessan Pezeshki, Mahboob ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOGLYCOSIDE; ANTIOXIDANT; ATORVASTATIN; CARBOPLATIN; CISPLATIN; CREATININE; CYCLOSPORIN; CYSTATIN C; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODINATED CONTRAST MEDIUM; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; BLADDER CANCER; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED NEPHROTOXICITY; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIUM CANCER; EVENING DOSAGE; EVENT FREE SURVIVAL; FANCONI RENOTUBULAR SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPERURICEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TUBULE ACIDOSIS; KIDNEY TUBULE DISORDER; KIDNEY VASCULAR RESISTANCE; LIPID PEROXIDATION; LOW DRUG DOSE; LUNG CANCER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORNING DOSAGE; NEPHROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OVARY CANCER; OXIDATIVE STRESS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; SALT WASTING; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TESTIS CANCER; THROMBOTIC THROMBOCYTOPENIC PURPURA; UTERINE CERVIX CANCER;

ANIMALS; ANTI-BACTERIAL AGENTS; CYTOTOXINS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES;

EID: 84885998629     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3t30f     Document Type: Review

References (81)

1. Nolin TD, Himmelfarb J. Drug-induced kidney disease, in Dipiro JT(eds), Pharmacotherapy, a pathophysiologic approach. 8th ed: Mc Graw Hill companies Inc, New York, 2011.
2. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: A review. Am J Med Sci, 2007; 334(2):115-124
3. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol, 2005; 19(1): 117-125
4. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis, 2005; 45(1): 2-14
5. Sharyo S, Yokota-Ikeda N, Mori M, Kumagai K, Uchida K, Ito K, Burne-Taney MJ, Rabb H, Ikeda M. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int, 2008; 74(5):577-584
6. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Takeuchi M, Maeda S, Yamagishi S. Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxid Med Cell Longev, 2010; 3(5):304-307
7. Ozbek E, Cekmen M, Ilbey YO, Simsek A, Polat EC, Somay A. Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-κB pathway. Ren Fail, 2009; 31(5):382-392
8. Chen HH, Chen TW, Lin H. Pravastatin attenuates carboplatin-induced nephrotoxicity in rodents via peroxisome proliferator-activated receptor α-regulated heme-oxygenase-1. Mol Pharmacol, 2010; 78(1):36-45
9. Haendeler J, Hoffmann J, Zeither AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: A novel vasculoprotective function of statin. Circulation, 2004; 110(7):856-861
10. Park JK, Müller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schäfer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H, Cerivastatin prevents angiotensin IIinduced renal injury independent of blood pressureand cholesterol lowering effects. Kidney Int, 2000; 58(4): 1420-143
11. Ichiki T, Takeda K, Tokunou T, Lino N, Egashira K, Shimokawa H, Hiarno K, Kanaide H, Takeshita A. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2001; 21(12):1896-190
12. Hernàndez-Perera O, Pérez-Sala D, Navarro-Antolín I, Sànchez-Pascuala R, Hernàndez G, Díaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelia nitric oxide synthase in vascular endothelial cells. J Clin Invest, 1998; 101(12):2711-2719
13. Mason JC, Ahmed Z, Mankoff R, Lidington EA, Ahmad S, Bhatia V, Kinderlerer A, Randi AM, Haskaoud D. Statin-induced expression of decayaccelerated factor protects vascular endothelium against complement-mediated injury. Circ Res, 2002; 91(8):696-703
14. Li JH, He NS. Prevention of iodinated contrastinduced nephropathy. Chin Med J, 2009; (Engl) 124(23):4079-4082
15. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA. Pathophysiology of contrast-induced nephropathy. Am J Cardiol, 2006; 98(6A):14K-20K
16. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. Am J Roentgenol, 2004; 183 (6): 1673-1689
17. Hung YM, Lin SL, Hung SY, Huang WC, Wang PY. Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography. World J Cardiol, 2012; 4(5):157-172
18. Al-Otaibi KE, Al Elaiwi AM, Tariq M, Al-Asmari AK. Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase and nitric oxide." Oxid Med Cell Longev, doi:10.1155/2012/831748
19. Attalah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol, 2004; 62(4): 273-278
20. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, Moscucci M. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med, 2005; 118(8):843-849
21. Patti G, Nusca A, Chello M, Pasceri V, D' Ambrosio A, Vetrovec GW, Di Sciascio G. Usefulness of statin pretreatment to prevent contrast-induced nephropathy to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2008; 101(3):279-285
22. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, Youn TJ, Chung WY, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angioplasty (PROMISS) trial-a randomized controlled study. Am Heart J, 2008; 155(3): 499.e1-499.e8
23. Zhao JL, Yang YJ, Zhang YH, You SJ, Wu YJ, Gao RL. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J cardiol, 2008; 126(3):435-436
24. Bouzas-Mosquera A, Vázquez-Rodríguez JM, Calviño-Santos R, Vázquez-González N, Castro-Beiras A Statin therapy and contrast-induced nephropathy after primary angioplasty. Int J Cardiol, 2009; 134(3):430-431
25. Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, Guozhen H, Yunfa J, Weili W, Shiqiang L. Comparison of usefulness of simvastatin 20mg versus 80mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol, 2009; 104(4):519-524 (Abstract was used)
26. Yoshida S, Kamihata H, Nakamura S, Senoo T, Manabe K, Motohiro M, Sugiura T, Iwasaka T. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol, 2009; 54(2): 192-198
27. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F. Usefulness of atorvastatin 80mg in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol, 2010; 105(3):288-292
28. Kandula P, Shah R, Singh N, Markwell S, Bhensdadia N, Davaneethan SD. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. Nephrology, 2010; (Carlton) 15(2):165-170
29. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, Yalcin S, Alemdar R. Efficacy of short-term highdose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology, 2010; 61(7):711-714
30. Acikel S, Muderrisoglu H, Yildirir A, Aydinalp A, Sade E, Bayraktar N, Bal U, Ozin B. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis, 2010; 21(8):750-757
31. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, Montinaro A, Sciascio GD. Shortterm, high-dose storvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention (from the ARMYDA-CIN [Atortvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial). Am J Cardiol, 2011; 108(1):1-7
32. Muñoz MA, Maxwell PR, Green K, Hughes DW, Talbert RL. Pravastatin versus simvastatin for prevention of contrast-induced nephropathy. J Cardiovasc Pharmacol Ther, 2011; 16(3-4):376-379
33. Li W, Fu X, Wang Y, Li X, Yang Z, Wang X, Geng W, Gu X, Hao G, Jiang Y, Fan W, Wu W, Li S. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute STsegment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology, 2012; 22(3):195-202
34. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, Ricciardelli B, Donnarumma E, Bianco A, Zabatta MA, Troncone G, Colombo A, Briguori C, Condorelli G. Impact of high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation, 2012; 126(25): 3008-3016
35. Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: A metaanalysis. Int J Cardiol, 2011;151(3):348-353
36. Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol, 2011; 33(4):344-351
37. Takagi H, Umemoto T. A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy. Int J Cardiol, 2011; 153(3):323-337
38. Zhou Y, Yuan WJ, Zhu N, Wang L. Short-term, highdose statins in the prevention of contrast-induced nephropathy; a systematic review and meta-analysis. Clin Nephrol, 2011; 76(6):475-483
39. Zhang L, Zhang L, Lu Y, Wu B, Zhang S, Jiang H, Ge J, Chen H. Efficacy of statin pretreatment for the prevention of contrast-induced nephropathy: a metaanalysis of randomized controlled trials. Int J Clin Pract, 2011; 65(5):624-630
40. Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol, 2011; 27(6):851-858
41. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of shortterm high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. Plos One, 2012; 7(4):e34450
42. Kwok CS, Pang CL, Yeong JK, Loke YK. Measures used to treat contrast-induced nephropathy: overview of reviews. Br J Radiol, 2013; 86(1021): 20120272
43. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insight into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int, 2011; 79(1): 33-45
44. Ozbek E, Cekmen M, Ilbey YO, Simsek A, Polat EC, Somay A. Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-κB pathways. Ren Fail, 2009; 31(5):382-392
45. Antoine DJ, Srivastava A, Pirmohamed M, Park BK. Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells. Biochem Pharmacol, 2010; 79(4):647-654
46. Jabari M, Rostami Z, Jenabi A, Zahedi-Shoolami L, Mooraki A. Simvastatin ameliorates gentamicininduced renal injury in rats. Saudi J Kidney Dis Transpl, 2011; 22(6): 1181-1186
47. Iranian Registry of Clinical Trials. IRCT201301283449N11.
48. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanisms, incidence, risk factors and special populations. A literature review. Eur J Clincal Pharmacol, 2012; 68(9):1243-1255
49. Ladino M, Alex M, Schulman IH. Acute and reversible vancomycin nephrotoxicity: a case series. J Nephrol Res Transplant, 2008; 3:4-10
50. Nishino Y, Takemura S, Minamiyama Y, Hirohash K, Ogino T, Inoue M, Okada S, Kinoshita H. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Rad Res, 2003; 37(4):372-379
51. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med, 2011; 123(2): 182e1-7
52. King DW, Smith MA. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro, 2004; 18(6):797-803
53. Panonnummal R, Varkey J, Dinoop DR. Protective effects of atorvastatin against vancomycin induced nephrotoxicity in albino rats. Pharmacie Globale [IJCP], 2011; 2(8):1-6
54. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel), 2011; 2(11): 2490-2518
55. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol, 2009; 61(3):223-242
56. Ramesh G, Reeves WB. P38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol, 2005; 289(1):F166-174
57. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res, 2003; 9(1):10-19
58. Li S, Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, Portilla D. PPAR ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol, 2004; 286(3):F572-F580
59. İşeri S, Ercan F, gedik N, Yüksel M, Alican İ. Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology, 2007; 230(2-3):256-264
60. Fujieda M, Morita T, Naruse K, Hayashi Y, Ishihara M, Yokoyama T, Toma T, Ohta K, Wakuguchi H. Effects of pravastatin on cisplatin-induced nephrotoxicity in rats. Hum Exp Toxicol, 2010; 30(7): 603-615
61. Roudier E, Mistafa O, Stenius U. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostaic drugs. Mol Cancer Ther, 2006; 5(11):2706-2715
62. Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, Toksoz D. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6kinase activity. Cancer Res, 2007; 67(20):9878-9886
63. Sharyo S, Yokota-Ikeda N, Mori M, Kumagai K, Uchida K, Ito K, Burne-Taney MJ, Rabb H, Ikeda M. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathay. Kidney Int, 2008; 74(5): 577-584
64. An Y, Xin H, Yan W, Zhou X. Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice. Exp Toxicol Pathol, 2011; 63(3): 215-219
65. Khoshnoud MJ, Abdeh Moghbel BN, Geramizadeh B, Niknahad H. Effect of simvastatin on cisplatininduced nephrotoxicity in male rats. Iranian Journal of Pharmaceutical Sciences, 2011; 7(3): 165-173
66. Cheng CF, Juan SH, Chen JJ, Chao YC, Chen HH, Lian WS, Lu CY, Chang CI, Chiu TH, Lin H. Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis, 2008; 13(7):883-894
67. Naesens M, Kuypers DRS, Sarwal M. calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol, 2009; 4(12):481-508
68. Li C, Yang CW, Park JH, Lim SW, Sun BK, Yung JY, Kim SB, Kim YS, Kim J, Bang BK. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporineinduced nephropathy. Am J Physiol Renal Physiol, 2004; 286(1):F46-F57
69. Nam HK, Lee SJ, Kim MH, Rho JH, Son YK, Lee SM, Kim SE, Kim KH, An WS. Rosuvastatin attenuates inflammation, apoptosis, and fibrosis in a rat model of cyclosporine-induced nephropathy. Am J Nephrol, 2013; 37(1): 7-15
70. Shahbazi F, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. J Pharm Pharm Sci, 2012; 15(1):112-123
71. Nassiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. A review of the potential protective effects of pentoxifylline against druginduced nephrotoxicity. Eur J Clin Pharmacol, 2012; 69(5):1057-1073
72. Jafari A, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. Potential nephroprotective effects of Lcarnitine against drug induced nephropathy: A review of Literature. Exp Opin Drug Saf, 2013. Epub ahead of print.
73. Hosseinjani H, Moghaddas A, Khalili H. Nacetylcysteine for the prevention of non-contrast media agent-induced kidney injury. From preclinical to clinical evidence. Eur J Clin Pharmacol, 2013; 69(7):1375-1390
74. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and metaanalysis. Eur J Cancer, 2013. Epub ahead of print. Doi;1D.1016/j.ejca.2013.04.030
75. Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer; a systematic review and metaanalysis. Ann Oncol, 2013. Epub ahead of print.
76. Bjarnadottir O, Romero Q, Bendahl PO, Jirström K, Rydén L, Loman N, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat, 2013; 138(2):499-508
77. Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenge in renal transplantation. Am J Transplant, 2012; 12(8): 1975-1982
78. Maharjan N, Bedi U, Arora R, Bhandari S, Dahal P, Khosla S. Impact of statins on cardiovascular outcomes in renal transplant recipients: a systematic review. Am J Ther, 2011; 18(3):e48-e54
79. Mehra MR, Raval NY. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc, 2004; 36(5):1539-1541
80. Stein W, Schrepfer S, Itoh S, Kimura N, Vellotta J, Palmer O, Bartos J, Wang X, Robbins RC, Fischbein MP. Prevention of transplant coronary artery disease by prenylation inhibitors. J Heart Lung Transplant, 2011; 30(7):761-769
81. Solid organ transplantation. In: Dipiro JI, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (editors). Pharmacotherapy: a pathophysiologic approach. 8th edition. McGraw-Hill, 2011.